Have any questions?
+44 1234 567 890
Management of Patients affected by EoE and other Eosinophilic Gastro-Intestinal Disorders during Coronavirus disease (COVID-19) pandemic
In March 2020, COVID-19 disease became pandemic and, nowadays, represents a worldwide problem. Clinicians have to deal with this new entity, and continuing to provide the best care to patients with other diseases. In this setting, it is challenging to know if common indications dispensed to our patients remain valid .
The aim of this document is to provide a support for clinicians to make decisions about the management of eosinophilic gastrointestinal disorders (EGIDs). Information contained in this manuscript are produced by a team of experts on EGIDs, after revision of the available literature and collective discussion. We think that sharing these information can help clinicians to offer the best treatment to their patients, especially to those at higher risk of SARS-CoV-2 infection, in particular those with ongoing immunosuppressive therapy.
This document should be considered as an additional guidance and not substitutive of statements provided by international medical authorities such as the World Health Organization, the European and US Center for Disease Prevention and Control and Official National health care authorities, that must be prioritized.
As the knowledge on COVID-19 is rapidly increasing, also these recommendations could be updated or changed in parallel.